| abstract |
Her-2 / neu protein expression on circulating cancer cells in blood or peripheral blood mononuclear cell (PBMC) samples is detected by a sensitive Her-2 / neu immunoassay. It is not necessary to isolate the cancer cells before performing the immunoassay. A positive result indicates Her-2 / neu expression on cancer cells in the blood sample. Cancers likely to benefit from treatment with anticancer agents such as trastuzumab (HERCEPTIN), lapatinib, CP-724, 714, NKI-272, and BMS-596626 targeting Her-2 / neu using this method Patients can be identified. |